Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab with Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer
NCT05588219Phase 2Recruiting
- Start
- Dec 2022
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in Cervical Cancer (CC). Primary endpoint: Tumor regression ratio at 2 weeks. Started Dec 2022; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT05588219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05588219.